LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE Drug Patent Profile

Which patents cover Lidocaine Hydrochloride W/ Epinephrine, and what generic alternatives are available?

Lidocaine Hydrochloride W/ Epinephrine is a drug marketed by Abbott, Bel Mar, Dell Labs, Intl Medication, and Watson Labs. and is included in eight NDAs.

The generic ingredient in LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE is epinephrine; lidocaine hydrochloride. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the epinephrine; lidocaine hydrochloride profile page.

Summary for LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

US Patents:	0
Applicants:	5
NDAs:	8
Clinical Trials:	262
DailyMed Link:	LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE at DailyMed

Recent Clinical Trials for LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Goldman, Butterwick, Fitzpatrick and Groff	PHASE4
King Abdulaziz University	NA
University of Pennsylvania	PHASE1

See all LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE clinical trials

US Patents and Regulatory Information for LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	083154-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	080377-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Dell Labs	LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	083389-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: September 5, 2026

Lidocaine hydrochloride with epinephrine is a mature, multisource injectable anesthetic market with limited patent protection, low differentiation, and price-driven competition. Financial performance depends more on hospital contracts, supply reliability, manufacturing efficiency, presentation, and shortage conditions than on exclusivity. No single company reports global revenue for the combination as a standalone product, and the product name covers multiple strengths, vial sizes, cartridges, and routes of administration.

Lidocaine Hydrochloride With Epinephrine Market Dynamics, Patents, FDA Status, and Financial Outlook

What is the market structure for lidocaine hydrochloride with epinephrine?

The market consists primarily of generic injectable products used for local or regional anesthesia. Lidocaine hydrochloride is the active anesthetic. Epinephrine is added to reduce local blood flow, slow systemic absorption, prolong anesthesia, and reduce bleeding at the injection site.

Common presentations include:

Presentation	Typical clinical use	Primary buyers
0.5% injection with epinephrine	Local infiltration and selected regional anesthesia	Hospitals, ambulatory surgery centers
1% injection with epinephrine	Dental, dermatologic, surgical, and emergency procedures	Dental distributors, hospitals, clinics
2% injection with epinephrine	Higher-concentration local anesthesia	Hospitals, dental practices, specialty clinics
Cartridges	Dental anesthesia	Dental distributors and practitioners
Multi-dose vials	Institutional procedures	Hospitals and outpatient facilities
Single-dose vials or ampules	Operating rooms and procedural settings	Hospitals and surgery centers

The market is fragmented among generic injectable manufacturers, contract manufacturers, specialty pharmaceutical suppliers, dental-product companies, and hospital distributors. Major commercial competition is generally based on:

• Contract price
• Availability and fill rate
• Product presentation
• Preservative status
• Stability and shelf life
• Container-closure configuration
• Regulatory compliance
• Distributor relationships
• Ability to maintain supply during shortages

The product is usually purchased through group purchasing organizations, hospital wholesalers, dental distributors, and direct institutional contracts. Retail pharmacy exposure is limited compared with oral medicines.

What is the FDA regulatory status of lidocaine hydrochloride with epinephrine?

Lidocaine hydrochloride injection with epinephrine is an FDA-approved prescription drug category. Products are generally approved through abbreviated new drug applications or, for some legacy products, earlier approval pathways. The products are not biologics and do not face biosimilar substitution dynamics.

FDA-regulated issues include:

• Sterility assurance
• Potency and assay of lidocaine and epinephrine
• Uniformity of the combination
• Particulate control
• Container-closure integrity
• Preservative concentration where applicable
• Stability of epinephrine
• Labeling for route, concentration, and maximum dose
• Manufacturing controls for sterile injectable products

The combination is available in multiple approved strengths and dosage forms. FDA labeling generally warns against intravenous administration of formulations intended for local infiltration and describes contraindications and precautions involving epinephrine-sensitive conditions, sulfite sensitivity, cardiovascular disease, and accidental intravascular injection. Product-specific labeling controls whether a formulation contains preservatives or sulfites. [1]

What is the Orange Book status of lidocaine hydrochloride with epinephrine?

The Orange Book does not create market exclusivity for the active ingredient. Lidocaine is an old small-molecule drug, and generic injectable versions have been available for decades.

Orange Book treatment is product-specific. A particular lidocaine hydrochloride and epinephrine product may have an approved listing, but the commercial combination is not protected by a single Orange Book patent estate comparable to a newer branded medicine. Product-level patent information depends on the specific application number, strength, dosage form, and sponsor.

The practical implication is that ordinary generic entry is already established. Competition is not waiting for a central patent expiry date.

When does lidocaine hydrochloride with epinephrine lose exclusivity?

The product has effectively lost core market exclusivity. Lidocaine and epinephrine are established active ingredients with extensive generic competition and no meaningful remaining composition-of-matter exclusivity for the ordinary injectable combination.

Exclusivity category	Commercial position
Active-ingredient patent	Expired or not relevant to current generic supply
Core combination patent	No broadly controlling patent identified for the standard injectable product
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Not a central market factor
Biosimilar exclusivity	Not applicable
Formulation exclusivity	May exist for specific products but does not control the ordinary market
Device or container exclusivity	May apply to a particular presentation
Manufacturing-process patents	May protect a process but usually do not block all generic supply

The remaining legal value is product-specific. A manufacturer may obtain protection for a specialized cartridge, prefilled syringe, delivery system, concentration, preservative profile, or manufacturing method. Those rights do not generally establish broad exclusivity over lidocaine hydrochloride with epinephrine.

What patents protect lidocaine hydrochloride with epinephrine?

The standard injectable combination has a weak patent estate. Commercial protection is more likely to arise from secondary rights than from the active ingredients.

Formulation patents

Potentially protectable features include:

• Reduced-degradation formulations
• Specific pH ranges
• Sulfite or preservative systems
• Low-particle formulations
• Extended stability
• Compatibility with particular containers
• Premixed or ready-to-use presentations
• Concentration-specific compositions

A formulation patent must distinguish the claimed product from decades of prior art involving lidocaine, epinephrine, preservatives, buffers, antioxidants, and sterile aqueous injection systems. That makes broad claims difficult to sustain.

Device and presentation patents

A prefilled syringe, dental cartridge, injection device, or proprietary delivery system may create a narrower patent position. These rights can support price differentiation if the device improves handling, dosing accuracy, safety, or procedural efficiency.

Method-of-use patents

Method-of-use protection is limited for routine local anesthesia because the principal uses are longstanding. A patent directed to a specific procedure, patient population, administration protocol, or combination technique could have value, but it would not generally prevent use of ordinary generic lidocaine with epinephrine for established procedures.

Manufacturing patents

Manufacturing rights can cover impurity control, sterile filling, epinephrine stabilization, packaging, or high-throughput production. These patents may raise the cost of designing around a process but usually do not prevent competitors from using alternative methods.

Are there Paragraph IV challenges for lidocaine hydrochloride with epinephrine?

Paragraph IV litigation is not a major market driver for the conventional product. A Paragraph IV certification is relevant when an abbreviated new drug applicant challenges a listed patent for a reference product. Because ordinary lidocaine hydrochloride with epinephrine is already a mature generic category, the principal competitive event is usually ANDA approval and commercial supply, not a high-value patent challenge against a single branded product.

Paragraph IV risk can arise for:

• A newly approved proprietary formulation
• A prefilled syringe
• A specialized dental cartridge
• A device-linked product
• A high-value combination presentation
• A product with listed formulation or method-of-use patents

For standard multi-dose vials and single-dose injections, patent litigation is unlikely to be the primary barrier to entry.

Which companies compete in the market?

Competition is divided between large injectable manufacturers and specialty suppliers. The relevant supplier set can change by country and by hospital contract cycle.

In the United States, generic injectable and local-anesthetic supply has historically included companies such as:

• Fresenius Kabi
• Pfizer and its legacy Hospira business
• Hikma Pharmaceuticals
• Eugia Pharma Specialties
• Sagent Pharmaceuticals
• Eugia-associated institutional suppliers
• Dental product companies and regional distributors
• Contract manufacturers supplying private-label products

The precise competitive set differs by strength, container, NDC, and availability. A company may have an approved product without being an active supplier in every period.

Market share is often measured by units, not revenue. A low-priced vial can represent substantial unit volume while producing modest sales. Dental cartridges have different economics from hospital vials and should not be combined without adjusting for presentation and channel.

What drives revenue for lidocaine hydrochloride with epinephrine?

Revenue is driven by volume and contract position rather than therapeutic innovation.

Key revenue variables are:

1. Procedure volume. Dental procedures, minor surgery, dermatology, emergency medicine, and outpatient interventions support recurring demand.
2. Presentation mix. Prefilled syringes and cartridges can generate higher revenue per dose than bulk vials.
3. Institutional contracting. Group purchasing organizations and hospital systems exert strong price pressure.
4. Shortage conditions. Temporary supply disruptions can increase realized prices and shift share to available suppliers.
5. Manufacturing yield. Sterile injectable production has high fixed costs and quality-control requirements.
6. Product withdrawals. A recall or manufacturing interruption can move demand rapidly to competitors.
7. Epinephrine stability. Degradation, discoloration, and packaging sensitivity increase quality and inventory-management costs.
8. Freight and storage. Injectable products require controlled logistics and careful inventory rotation.
9. Regulatory compliance. Warning letters, inspection findings, or remediation costs can materially affect profitability.

No standalone public revenue figure reliably represents all lidocaine hydrochloride with epinephrine sales. Public-company disclosures generally aggregate the product into broader injectable, hospital, anesthesia, or generic segments.

How strong is the patent estate for lidocaine hydrochloride with epinephrine?

The patent estate is weak for the conventional product and potentially stronger for differentiated delivery formats.

Asset type	Patent strength	Commercial effect
Lidocaine active ingredient	Very low	No meaningful current exclusivity
Epinephrine active ingredient	Very low	No meaningful current exclusivity
Standard aqueous injection	Low	Broad generic substitution
Preservative-specific formulation	Low to moderate	Product-specific differentiation
Prefilled syringe	Moderate	Can support presentation-level barriers
Dental cartridge	Low to moderate	Primarily manufacturing and channel protection
Sterile manufacturing process	Moderate	Raises design-around and compliance costs
Proprietary delivery device	Moderate to high	Can support differentiated pricing
Method of use	Low for routine procedures	Narrow procedural relevance

The main commercial moat is operational, not patent-based. Manufacturers with reliable sterile capacity, validated suppliers, strong quality systems, and institutional contracts can outperform competitors despite having little or no enforceable exclusivity.

What patent litigation affects the market?

Patent litigation is not a defining feature of the conventional lidocaine hydrochloride with epinephrine market. Litigation risk is more likely to affect specialized products than ordinary generic injections.

Relevant disputes would generally involve:

• Product-specific formulation patents
• Device patents
• Trade dress or packaging
• ANDA certifications
• Manufacturing processes
• Regulatory exclusivity for a reformulated product
• Contract and supply disputes

In practice, regulatory enforcement, manufacturing observations, recalls, and shortage-related procurement events can have greater commercial impact than patent lawsuits. FDA enforcement records and product-specific court dockets are necessary to determine whether a particular sponsor or NDC is involved in active litigation. [2, 3]

What generic entry risks exist?

Generic entry is already embedded in the market. The principal risk for an incumbent is not first generic entry but additional supplier entry and price compression.

Generic launch scenarios

Scenario	Expected market effect
New supplier enters standard vial market	Lower contract prices and reduced incumbent volume
New supplier enters during shortage	Rapid share capture and potentially higher short-term pricing
New cartridge supplier enters dental channel	Distributor switching and contract repricing
Proprietary prefilled product launches	Segment expansion with less direct price comparison
Incumbent manufacturing interruption	Temporary share transfer and back-order exposure
FDA quality action	Supply disruption, recall costs, and customer loss

A new entrant must overcome sterile manufacturing costs, validation requirements, supplier qualification, product liability exposure, and buyer qualification processes. These barriers slow entry but do not produce durable exclusivity.

How does lidocaine hydrochloride with epinephrine compare with plain lidocaine?

Factor	Lidocaine hydrochloride alone	Lidocaine hydrochloride with epinephrine
Clinical positioning	Local anesthesia	Local anesthesia with longer local effect and reduced bleeding
Manufacturing complexity	Lower	Higher because of epinephrine stability and formulation control
Market demand	Broad	Broad but procedure-specific
Patent position	Weak	Weak for standard products
Pricing power	Low	Low to moderate by presentation
Shortage sensitivity	High	High
Product differentiation	Limited	Greater through concentration, cartridge, syringe, and preservative profile
Regulatory complexity	Standard injectable controls	Additional combination and stability considerations

Epinephrine-containing products can command a modest presentation premium, but hospital purchasing systems often compare them as generic injectables. Clinical substitution is limited by the procedure and the prescriber’s choice, yet supplier substitution remains common.

What is the financial trajectory for the market?

The long-term trajectory is mature and low-growth in unit terms. Revenue is likely to track procedure volumes, population growth, outpatient care, dental activity, and inflation rather than new indications.

The likely financial pattern is:

• Stable baseline demand
• Low or declining prices under competitive contracts
• Periodic price increases during shortages
• Margin volatility from sterile manufacturing costs
• Higher margins for differentiated delivery formats
• Limited return from conventional commodity vials
• Greater value in supply reliability than in patent ownership

A manufacturer focused only on standard vials faces a low-margin business. A company with efficient sterile capacity, reliable epinephrine formulation control, dental distribution, prefilled devices, or a shortage-resilient supply chain may achieve better economics.

What manufacturing and geographic barriers matter?

The principal barriers are regulatory and operational.

Manufacturing barriers

• Aseptic processing
• Sterile filtration and filling
• Validated cleaning procedures
• Container-closure integrity
• Epinephrine oxidation control
• Particulate and endotoxin control
• Reliable glass, rubber, syringe, and cartridge supply
• Stability testing across storage conditions
• Inspection readiness

Geographic coverage

The product is sold globally, but approval and substitution rules differ by market. In the United States, FDA approval, NDC registration, institutional contracting, and shortage reporting are central. In Europe, national or decentralized marketing authorizations and hospital tenders influence pricing. Emerging markets may rely more heavily on local manufacturing, import registration, and government procurement.

A global supplier needs country-specific packaging, labeling, pharmacopoeial compliance, and distribution arrangements. Geographic expansion does not automatically create pricing power because local anesthetic injections are commonly treated as tendered generic products.

What is the outlook for licensing and partnerships?

Licensing value is limited for the conventional injectable combination. Transactions are more likely to involve:

• Contract manufacturing
• Private-label supply
• Regional distribution
• Dental-channel commercialization
• Prefilled syringe technology
• Hospital portfolio acquisitions
• Supply agreements linked to shortage resilience

A license covering only standard lidocaine hydrochloride with epinephrine is unlikely to command substantial economics unless it includes a differentiated formulation, delivery device, regulatory approvals, or protected geographic rights.

Key Takeaways

• Lidocaine hydrochloride with epinephrine is a mature generic injectable category.
• Core active-ingredient and standard formulation exclusivity has no meaningful commercial relevance.
• Patent value is concentrated in specialized formulations, devices, cartridges, packaging, and manufacturing methods.
• Paragraph IV litigation is not a major driver for ordinary vial products.
• Revenue is fragmented and rarely disclosed as a standalone line item.
• Hospital contracts, dental distribution, supply reliability, and shortage conditions determine commercial performance.
• Standard products face persistent price pressure and limited pricing power.
• Prefilled syringes, proprietary delivery systems, and reliable sterile manufacturing offer the strongest routes to margin improvement.
• Biosimilar risk is not applicable because the product is a small-molecule injectable, not a biologic.
• The market outlook is stable in demand but structurally low-growth and operationally sensitive.

FAQs

Is lidocaine hydrochloride with epinephrine a generic drug?

Yes. Conventional injectable presentations are widely supplied as generic prescription products. Individual products remain subject to FDA approval and manufacturing requirements.

Does lidocaine with epinephrine have biosimilar competition?

No. Biosimilars apply to biologic products. Lidocaine hydrochloride with epinephrine is a small-molecule drug, so competition occurs through generic injectable approvals.

Can a company patent a new lidocaine and epinephrine product?

Yes, but protection would generally need to cover a novel formulation, delivery device, container, manufacturing process, or specific use. A broad patent on the ordinary combination would face extensive prior art.

Why can prices rise if the product has no meaningful patent protection?

Sterile injectable manufacturing has concentrated capacity, high compliance costs, and vulnerable supply chains. A recall, plant shutdown, raw-material shortage, or container shortage can reduce supply and raise short-term prices.

Is the dental cartridge market more attractive than the hospital vial market?

It can be. Dental cartridges may support stronger channel relationships, presentation-specific differentiation, and higher revenue per dose. The segment remains price-sensitive and depends on distributor access, product reliability, and regulatory compliance.

References

1. U.S. Food and Drug Administration. (n.d.). Lidocaine hydrochloride and epinephrine injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm